Myopia

The first Australian data into the efficacy of repeated low-level red-light (RLRL) has been published in what is shaping to...

The Essilor Stellest lens, clinically proven to slow myopia progression in children,^1 has now been evaluated in two studies for...

The inventor of the Eyerising International repeated low-level red light (RLRL) therapy for myopia, Professor Mingguang He, has outlined “notable...

The latest one-year and two-year results from ongoing multi-centre trials of ZEISS MyoCare lenses consistently demonstrate the slowing of progressive...

At the completion of this article, the reader should be able to improve their knowledge of emerging myopia control interventions,...

EssilorLuxottica has unveiled new six-year clinical data at the 2025 China Optometry & Ophthalmology Conference (COOC), reinforcing the long-term efficacy...

Sydney optometrist DR OLIVER WOO explains why colleagues need to be on the look out for pre-myopes and how prescribing...

There’s a lot to think about when faced with a progressing myope. Is their script up to date? Is the...

CooperVision’s MiSight 1 day is a key product helping slow the progression of myopia in children. As optometry increasingly embraces...

Korea-based global pharmaceutical company Celltrion has announced approval from the Therapeutic Goods Administration (TGA) of Australia of its ophthalmic treatment...